Circulating miRNA markers show promise as new prognosticators for multiple myeloma
暂无分享,去创建一个
J. Byrd | A. Palumbo | L. Cascione | C. Hofmeister | F. Pichiorri | A. Ferro | M. Boccadoro | D. Rossi | V. Callea | H. Alder | S. Bringhen | D. Benson | Y. Efebera | S. Geyer | V. Dirisala | A. Ferro | R. Ria | G. Isaia | B. Weiss | A. Palumbo | G. Isaia | G. Marcucci | G. Benevolo | A. Stiff | L. De Luca | T. Talabere | Emily M Smith | A. Rocci | M. Gambella | V. Magarotto | S. Gentili | S. Geyer | G. Uccello | P. Omedè | J. Consiglio | L. Luca | J. Guan | L. Cascione | E. M. Smith | M. Gambella | P. Omedè | Jessica A. Consiglio | Jingwen Guan | V. R. Dirisala | Andrew R. Stiff
[1] A. Allegra,et al. MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma , 2014, British journal of haematology.
[2] Je-Jung Lee,et al. Decreased body mass index is associated with poor prognosis in patients with multiple myeloma , 2014, Annals of Hematology.
[3] S. Ševčíková,et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance , 2014, Haematologica.
[4] Michael A. Freitas,et al. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation , 2013, The Journal of experimental medicine.
[5] Roberta Galli,et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response , 2012, Proceedings of the National Academy of Sciences.
[6] W. Tse,et al. Mutation of STAT1/3 binding sites in gp130(FXXQ) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential. , 2012, American journal of stem cells.
[7] Hajime Uno,et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. , 2011, Blood.
[8] G. Morgan,et al. Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[9] M. Boccadoro,et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Kantarjian,et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.
[11] Gabriele Sales,et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.
[12] M. Schemper,et al. The estimation of average hazard ratios by weighted Cox regression , 2009, Statistics in medicine.
[13] A. Neri,et al. Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles , 2009, Genes, chromosomes & cancer.
[14] L. D. Barnes,et al. Correlation of Fragile Histidine Triad (Fhit) Protein Structural Features with Effector Interactions and Biological Functions* , 2009, Journal of Biological Chemistry.
[15] C. Croce,et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.
[16] M. Goldsmith,et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. , 2006, Blood.
[17] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .